|Bid||153.05 x 100|
|Ask||158.13 x 100|
|Day's Range||154.13 - 157.41|
|52 Week Range||113.66 - 178.15|
|PE Ratio (TTM)||149.33|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||192.21|
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith live from the floor of the New York Stock Exchange to discuss the latest market moves.
Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.
Some of the biggest names in health care are bullish about the use of artificial intelligence in their industry, despite regulatory and data challenges.
Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.
Shares of Facebook have rewarded its investors incredibly well, but these Fools think you should take a look at these three stocks instead.
Vertex Pharmaceuticals Incorporated will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.
On April 6, 2018, Incyte (INCY) reported unfavorable results from its phase 3 ECHO-301/KEYNOTE-252 study, which evaluated the potential of the company’s investigational therapy, epacadostat, combined with Merck’s (MRK) Keytruda, in patients suffering from unresectable or metastatic melanoma as compared to those treated with Keytruda monotherapy. The trial failed to meet its first primary endpoint of improvement in progression-free survival and is also not expected to meet the second primary endpoint of overall survival. This news has had a drastic impact on Incyte’s stock, which fell ~22.9% from $83.07 on April 5, 2018, to $64.02 on April 6, 2018, and reduced the company’s market capitalization by approximately $3.5 billion.
Shares of Vertex Pharmaceuticals (VRTX) have easily outrun the market year-to-date, rising 8%, and the drug maker has notched returns of more than 42% in the past year. Analyst Hartaj Singh reiterated an Outperform rating and $190 price target on the shares Wednesday, but notes that Vertex could see as much as 50% upside to that target, which would put the shares at $285.
While the markets run up and down because tech stocks are doing one thing or another, or retailers struggle to improve same-store sales, there isn’t much debate about the future of the healthcare sector.Source: Shutterstock
Vertex Pharmaceuticals Incorporated today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018, and will report to Michael J.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently trading at a trailing P/E of 157.1x, which is higher than the industry average of 27.5x. While VRTX might seem like a stock toRead More...